Article

Extended-release formulation of venlafaxine in the treatment of post-traumatic stress disorder.

The Catholic University of Korea College of Medicine, Department of Psychiatry, Kangnam St. Mary's Hospital, Seoul 137-701, South Korea.
Expert Review of Neurotherapeutics (Impact Factor: 2.83). 07/2007; 7(6):603-15. DOI: 10.1586/14737175.7.6.603
Source: PubMed

ABSTRACT There is abundant evidence for abnormalities of both norepinephrine and serotonin neurotransmitter systems in post-traumatic stress disorder (PTSD). Venlafaxine extended-release formulation (venlafaxine XR) is a serotonin and norepinephrine re-uptake inhibitor with antidepressant and anxiolytic properties relevant to the pathophysiology of PTSD. Venlafaxine XR is currently approved for the treatment of panic disorder, generalized anxiety disorder and social anxiety disorder, as well as major depression in adults, based on a number of randomized, double blind, placebo-controlled clinical trials. Limited data also demonstrate that venlafaxine XR maintains a therapeutic response for more than 6 months in these anxiety disorders. Venlafaxine XR has demonstrated short- and long-term efficacy for the treatment of PTSD in two recent randomized, double-blind, placebo-controlled clinical trials, although it has not been extensively studied for PTSD, compared with other anxiety disorders. This review focuses on the potential role of venlafaxine XR in the treatment of PTSD, based on currently available evidence.

0 Followers
 · 
62 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background When treating Post Traumatic Stress Disorder (PTSD) we must consider its complexity as it presents a variety of often contrasting symptoms. The guidelines provided by the Society for Traumatic Stress Studies (ISTSS) consistantly suggests psychotherapy as the first course of action to be taken in both acute and cronic states of PTSD and recommends combining pharmacological treatment only in severe PTSD. However, considering the complexity of this clinical picture and the many neurobiological alterations in PTSD, medication seems to be a fundamental “ingredient” in the treatment of this disorder.
    Quaderni Italiani di Psychiatria 06/2009; 28(2):79-88. DOI:10.1016/j.quip.2008.11.013
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Discuss the theory of modulation of receptor activity or the blockade of the reuptake of multiple neurotransmitter systems for the future treatment of MDD. Major depressive disorder (MDD) is a serious and often crippling psychiatric illness with a high risk of relapse and treatment resistance. In this article, we discuss the role of the serotonergic system in MDD including our current understanding of how various serotonin (5HT) receptors modulate monoamine neurotransmission and behavior. We also discuss how pharmacologic interventions, including novel and existing antidepressants and atypical antipsychotics, may be utilized to adjust serotonergic neurotransmission and provide more effective treatments for patients with MDD.
    CNS spectrums 12/2014; 19 Suppl 1:54-68. DOI:10.1017/S1092852914000613 · 1.30 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Posttraumatic stress disorder (PTSD) is often comorbid with chronic migraine (CM) and chronic tension-type headache (CTTH). Trauma-focused cognitive behavioral psychotherapies, selective serotonin reuptake inhibitors (SSRIs), and venlafaxine have demonstrated efficacy in the treatment of PTSD. Amitriptyline, topiramate, sodium valproate, and botulinum toxin A are efficacious for treatment of chronic daily headache (CDH). Treatment studies on individuals with CDH and comorbid PTSD, however, are limited. As such, multiple therapeutic agents or modes of interventions typically are necessary, such that comprehensive treatment simultaneously utilizes approaches with established efficacy for each individual condition.
    Current Treatment Options in Neurology 10/2014; 16(10):312. DOI:10.1007/s11940-014-0312-7 · 2.18 Impact Factor